KAPA

Kairos Pharma, Ltd. (KAPA) ESG Analysis Analysis (2026)

Invetso Score: 5.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.0 (Moderate)

No disclosed R&D intensity or emissions metrics are provided, limiting evidence that KAPA manages environmental exposure better than peers in a materially regulated footprint.

The absence of reported capital-allocation data tied to decarbonization or resource efficiency makes peer-relative environmental positioning difficult to verify versus more transparent issuers.

With no disclosed environmental targets, transition plans, or sustainability disclosures in the supplied data, KAPA cannot be distinguished from peers on long-term environmental preparedness.

Environmental risk appears neither clearly advantaged nor clearly impaired versus peers based on available metrics, but disclosure gaps prevent a stronger relative score.

Social

Score:

No workforce, safety, turnover, or customer-impact metrics are provided, so KAPA’s social risk management cannot be shown to exceed peer norms.

Zero stock-based compensation as a share of revenue suggests limited dilution pressure, but it does not directly evidence stronger employee alignment or retention versus peers.

The lack of disclosed human-capital, product-responsibility, or community metrics leaves KAPA broadly comparable to peers on social transparency rather than demonstrably stronger.

Because the available data are sparse, social positioning is assessed as neutral-to-slightly-better than peers only on the basis of limited compensation-related dilution.

Governance

Score:

Debt-to-equity is reported at zero and net debt to EBITDA at 0.46, indicating a conservative balance-sheet structure that can reduce governance stress versus leveraged peers.

Zero stock-based compensation to revenue suggests restrained equity dilution, which is generally more shareholder-aligned than peers with heavier compensation issuance.

However, the provided metrics do not cover board independence, audit quality, ownership concentration, or controversy history, limiting confidence in a stronger governance assessment.

Overall governance appears modestly better than peers on capital discipline, but the absence of core oversight disclosures prevents a higher relative score.

Overall Score

Score:

KAPA’s ESG positioning is broadly in line with peers, with modest governance strength offset by limited environmental and social disclosure.

Score Driver: Conservative Leverage And Low Dilution Support Governance, But Sparse ESG Disclosure Prevents A Stronger Peer-Relative Assessment.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Kairos Pharma, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →